Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Pfizer moves to take PF-07934040 into its first clinical trial.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.